InDanio Bioscience, an early-stage drug discovery company founded by U of T researcher Dr. Henry Krause and his colleague Dr. Jen Tiefenchach to search for human nuclear receptors through the use of genetically engineered zebrafish. The research could lead to drug discoveries serving a lucrative market already estimated at $16 billion.
Last week, the Ontario Genomics Institute announced an investment of $100,000 in InDanio under its pre-commercialization business development fund. In the announcement, InDanion board member Dr. Paul Jefferson said that the investment would allow the company to identify the function of certain nuclear receptors and "thus form the basis for establishing commercial partnerships to further
characterize such receptors and develop drugs targeting them."
Writer: Edward Keenan
Sources: Alastair Harris-Cartwright, Corporate Communications Manager, OGI; John McCulloch,
MaRS blog